Lilly's blockbuster wins heart-risk indication; Teva to acquire marketed therapy
The FDA granted Eli Lilly's Mounjaro an expanded approval to lower the risk of serious heart problems. In a separate deal, Teva plans to purchase an existing approved medication. The announcement also touched on developments from AusperBio and Samsung Biologics.
Related stories
Roivant wins FDA approval for first oral dermatomyositis treatment · Drug development
J&J's Imaavy becomes first approved therapy for rare anemia · Drug development
TwinStrand wins patent lawsuit, GSK's hepatitis B drug gains Japan approval · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “Mounjaro scores FDA approval to reduce CV risk; Teva to buy an approved drug.” Browse more stories.